tubulin polymerization

Tubulin polymerization-IN-43 is an inhibitor of tubulin polymerisation.Tubulin polymerization-IN-43 has multiple effects, disrupting the cellular microtubule network by targeting the colchicine locus and promoting cell cycle arrest and apoptosis in leukaemia cells. Tubulin polymerisation-IN-43 has multiple effects, promoting leukaemia cell cycle arrest in G2/M phase and apoptosis by targeting Colchicine sites to disrupt the cellular microtubule network.

Tubulin Polymerization-IN-51 (compound 7u) serves as a tubulin polymerization inhibitor, exhibiting an IC50 range of 2.55 - 17.89μM against SK-Mel-28 cells, and is applicable in cancer research [1].

Tubulin polymerization-IN-53 (compound 4b) serves as an inhibitor of β-tubulin polymerization and is capable of arresting the cell cycle at the G2/M stage. It demonstrates antiproliferative efficacy against the MDA-MB-231 cell line, with an IC50 value of 3.24 μM [1].

Tubulin polymerization-IN-55 is a potent Tubulin Polymerization inhibitor with potential anti-angiogenic and anti-tumour activity, showing anti-proliferative effects against A549, K562, HepG2, MDA-MB-231 and HFL-1.

Tubulin Polymerization-IN-56 (compound 8l), an indazole derivative, potently inhibits tubulin polymerization by targeting the colchicine site, which induces cell cycle arrest and apoptosis. Additionally, this compound diminishes cell migration and significantly inhibits tumor growth in vivo [1].

Tubulin polymerization-IN-47 is a tubulin polymerization inhibitor and mitotic inhibitor with antitumor activity and inhibitory effects on neuroblastoma cancer cell proliferation, with IC50s of 7 and 12 nM for Chp-134 and Kelly cell lines, respectively. Tubulin polymerization-IN-47 is a candidate compound for the treatment of hepatocellular carcinoma, colon cancer, lung cancer and breast cancer.

Tubulin polymerization-IN-29 is a potent inhibitor of microtubule protein polymerization and shows potent anti-proliferative effects.Tubulin polymerization-IN-29 induces cell cycle arrest in HeLa cells at G2/M phase.

Tubulin polymerization-IN-45, a tubulin-targeting agent, acts as a tubulin polymerization inhibitor by binding to the tubulin's colchicine site. It induces apoptotic cell death in hepatocellular cancer (HCC) cells [1].

Tubulin polymerization-IN-46 (compound 9q) is a microtubule/tubulin inhibitor that impedes tubulin polymerization, induces apoptosis, and arrests MCF-7 breast cancer cells in the G2/M phase, exhibiting potent anti-proliferative activity with an IC50 of 10 nM [1].

Tubulin polymerization-IN-35 is [1,2] an inhibitor of oxazolylisoindole microtubulin polymerization that acts highly selectively on the marginal zone lymphoma VL51 cell line.

Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC 50 = 3.15 μM) that exhibits potent anti-vascular and anticancer activities including cancer cell apoptosis [1].

Tubulin polymerization-IN-39, a tubulin polymerization inhibitor with an IC50 of 4.9 μM, targets the colchicine-binding site to hinder tubulin polymerization. This compound effectively suppresses cancer cell proliferation.

Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor that inhibits the proliferation of cancer cells and can be used to study cancers such as lymphoma.

Tubulin polymerization-IN-26 (compound 12h) is a chemical compound that inhibits the polymerization of microtubulin. It achieves this by binding to the colchicine binding site of microtubulin, with an IC50 value of 4.64 μM. Additionally, Tubulin polymerization-IN-26 has the ability to induce apoptosis and inhibit cell metastasis or migration. Due to these properties, it holds potential as a valuable compound for researching lung cancer [1].

Tubulin polymerization-IN-9 is a potent inhibitor of tubulin (IC50: 1.82 μM). Tubulin polymerization-IN-9 arrests the cell cycle of K562 cells in G2/M phase and induces apoptosis and mitochondrial depolarization. Tubulin polymerization-IN-9 exhibits potent anti-vascular and anti-tumour effects.

Tubulin polymerization-IN-52 (compound SC23) effectively inhibits tubulin polymerization, exhibiting an IC50 value of 2.9 μM [1].

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

Tubulin polymerization-IN-6 (compound 5f) is a potent inhibitor of tubulin polymerization, with an IC50 of 1.09 μM. It not only inhibits cell migration and tube formation but also has anti-angiogenic properties. Additionally, Tubulin polymerization-IN-6 has been found to effectively hinder tumor growth in HT29 xenograft Balb/c nude mice [1].

Tubulin polymerization-IN-31 (Compound 4c) has antitumor activity and induces apoptosis of cancer cell. Tubulin polymerization-IN-31 is an inhibitor of tubulin polymerization with an IC 50 value of 3.64 μM [1].

Tubulin polymerization-IN-8 (compound IIc) is a potent inhibitor of tubulin polymerization that has been demonstrated to concentration-dependently induce cell cycle arrest at the G2/M phase in HCT116 tumor cells. It also significantly inhibits tubulin polymerization with an IC50 value of 12.7 μM, showing potential for cancer research [1].

Tubulin polymerization-IN-33 is an [1,2] inhibitor of oxazoloisoindole microtubulin polymerization and is a good anti-proliferative agent for NCI series cancer cells.

Tubulin polymerization-IN-10 is a highly potent inhibitor of tubulin polymerization, exhibiting an IC50 value of 4.25±0.75 μM. It possesses significant anti-tumor properties [1].

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin polymerization-IN-25 is a selective, dual tubulin polymerization (IC50: 1.11 μM) and farnesyl transferase (FTase) (IC50: 0.39 μM) inhibitor. polymerization-IN-25 exhibits cytotoxicity against cancer cells and blocks cell proliferation.

Tubulin polymerization-IN-4 is an effective inhibitor of tubulin polymerization (IC50=4.6 μM）。 Tubulin polymerization-IN-4 can destroy tubulin polymerization, block cell cycle at G2/M phase, induce apoptosis, and inhibit cell cloning and migration. Tubulin polymerization-IN-4 can also damage the vascular system.

Tubulinpolymer-in-44 (compound 7w) effectively inhibits Tubulin with an IC50 value of 0.21 μM and induces apoptosis by arresting the G2/M phase, making it useful for cancer research.

Tubulin polymerization-IN-24 (compound HMBA) is a potent inhibitor of tubulin polymerization that increase the GTP hydrolysis rate and inhibits microtubule assembly. Tubulin polymerization-IN-24 induces apoptosis and cell cycle arrest in G2/M phase. Tubulin polymerization-IN-24 inhibits proliferation of MCF-7 cells [1].

Tubulin polymerization-IN-30 (compound 6e) is a potent inhibitor of Tubulin polymerization. Tubulin polymerization-IN-30 can disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. Tubulin polymerization-IN-30 exhibits the high potency against the cancer cell lines including HeLa, SGC-7901 and A549 with IC 50 values of 0.403, 2.16 and 2.21 μM.

Tubulin polymerization-IN-13 (Compound 4f) is a potent inhibitor of tubulin polymerization, with an IC50 value of 0.37 μM. It displays significant anti-proliferative effects against cancer cells, inducing apoptosis and exhibiting potential antivascular activity [1].

Tubulin polymerization-IN-34 is an inhibitor of [1,2] oxazolylisoindole microtubulin polymerization and is highly selective for marginal zone lymphoma VL51 cell lines.

Tubulin polymerization-IN-22 arrests cell cycle at G2/M phase as well as induces apoptosis. Tubulin polymerization-IN-22 is an inhibitor of tubulin polymerization (IC 50 = 8.1 μM) [1].

Tubulin polymerization-IN-27 (compound 5j) is an inhibitor of tubulin polymerization. It has the ability to halt the cell cycle specifically at the G2 M phase and also induce apoptosis [1].

Tubulin Polymerization-IN-50 (compound 7n) serves as an inhibitor of tubulin polymerization, exhibiting an IC50 of 5.05 μM in SK-Mel-28 cells and inducing cell cycle arrest at the G2/M phase [1].

Tubulin polymerization-IN-48 (Compound 4k) is an inhibitor of tubulin polymerization, moderately disrupting the microtubule network. It impedes the proliferation of neuroblastoma cancer cells, exhibiting IC50 values of 79 nM and 165 nM for the Chp-134 and Kelly cell lines, respectively [1].

Tubulin Polymerization-IN-40 is an acridane-based inhibitor that potently disrupts tubulin polymerization, exhibiting an IC50 of 1.5 μM. It halts cancer cell progression at the G2/M phase, triggers apoptosis, and possesses anti-cancer properties along with immunopotentiating effects [1].

Tubulin polymerization-IN-36 is able to be used in cancer research, for example, lymphomas. Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding, that is an inhibitor of tubulin polymerization with IC50 of 2.8 μΜ[1].

Tubulin polymerization-IN-15 (compound 4) is a highly effective inhibitor of tubulin polymerization, with significant potential in cancer research [1].

Tubulin polymerization-IN-3 is a potent inhibitor of microtubulin polymerization (IC50: 3.84 μM) and induces apoptosis in colon cancer cells.

Tubulin polymerization-IN-49 (compound 12d), a potent inhibitor of tubulin polymerization, binds to the colchicine site on tubulin, subsequently inducing cell cycle arrest at the G2/M phase and triggering apoptosis. This compound exhibits anticancer activity by preventing tumor generation and inhibiting tumor proliferation and angiogenesis [1].

Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 μΜ) of tubulin polymerization by binding specifically to the colchicine site of tubulin and preventing colchicine binding. It has potential applications in cancer research, notably for lymphomas [1].

Tubulin aggregation-IN-17 (compound 23g) is a potent inhibitor of tubulin aggregation. tubulin aggregation-IN-17 has a microtubulin-depolymerising effect, induces apoptosis and inhibits migration. tubulin aggregation-IN-17 has potential for cancer disease research. Tubulin aggregation-IN-17 has potential for cancer disease research.

Tubulin aggregation-IN-18 (compound 3) is a potent tubulin aggregation inhibitor with potential for breast cancer and drug-resistant colon cancer studies.

Tubulin aggregation-IN-19 (compound 4) is a potent tubulin aggregation inhibitor that has shown potential in breast cancer and drug-resistant colon cancer.

Tubulin aggregation-IN-7 is a potent tubulin aggregation inhibitor that has shown research potential for cancer diseases.

Tubulin aggregation-IN-16 (compound 5g) is a potent inhibitor of tubulin aggregation. 16 effectively disrupts microtubule/tubulin dynamics and induces cell cycle arrest at G2/M phase in SGC-7901 cells.

Tubulin aggregation-IN-20 (compound 11) is a potent tubulin aggregation inhibitor. tubulin aggregation-IN-20 has the potential to be investigated in breast and drug-resistant colon cancer.

Valecobulin hydrochloride (CKD-516 hydrochloride) is a potent inhibitor of β-tubulin polymerization. Valecobulin hydrochloride is a valine prodrug and a vascular disrupting agent.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

Tubulin inhibitor 24 is a potent inhibitor that can inhibit tubulin polymerization.

Dolastatin 10 trifluoroacetate is a potent antimitotic polypeptide isolated from a marine animal and is developed as a potential antitumor agent. Dolastatin 10 is found to have an activity to inhibit tubulin polymerization (IC50: 1.2 μM). Besides that, it